Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

The eye does not have a way to remove floaters, so you will have them as long as you live unless you do something about it.

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

Jim Cramer, the host of Mad Money, recently took a deep dive into the challenges facing the consumer packaged goods sector, ...

WVU medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs such as Ozempic. Officials ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Cola’s office in Chicago's trendy West Loop, the soda giant’s iconic logo is noticeably absent. In its place is a giant ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...